HighTower Advisors LLC Sells 2,562 Shares of BioNTech SE (NASDAQ:BNTX)

HighTower Advisors LLC decreased its holdings in shares of BioNTech SE (NASDAQ:BNTX) by 18.9% in the 4th quarter, Holdings Channel.com reports. The firm owned 10,998 shares of the company’s stock after selling 2,562 shares during the quarter. HighTower Advisors LLC’s holdings in BioNTech were worth $1,253,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Jones Financial Companies Lllp boosted its holdings in BioNTech by 110.3% in the 4th quarter. Jones Financial Companies Lllp now owns 469 shares of the company’s stock valued at $53,000 after purchasing an additional 246 shares during the period. Quintet Private Bank Europe S.A. raised its position in BioNTech by 823.5% in the fourth quarter. Quintet Private Bank Europe S.A. now owns 785 shares of the company’s stock worth $88,000 after purchasing an additional 700 shares in the last quarter. GAMMA Investing LLC raised its position in BioNTech by 48.2% in the fourth quarter. GAMMA Investing LLC now owns 923 shares of the company’s stock worth $105,000 after purchasing an additional 300 shares in the last quarter. Generali Investments CEE investicni spolecnost a.s. acquired a new stake in BioNTech during the fourth quarter valued at approximately $137,000. Finally, AlphaCentric Advisors LLC acquired a new stake in BioNTech during the fourth quarter valued at approximately $168,000. Institutional investors and hedge funds own 15.52% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on BNTX shares. Canaccord Genuity Group restated a “buy” rating and issued a $171.44 target price on shares of BioNTech in a research note on Tuesday, March 11th. Citigroup began coverage on BioNTech in a research report on Thursday, March 13th. They set a “buy” rating and a $145.00 target price for the company. Wells Fargo & Company initiated coverage on shares of BioNTech in a report on Wednesday, December 11th. They issued an “overweight” rating and a $170.00 price objective on the stock. Truist Financial started coverage on BioNTech in a research note on Friday, January 10th. They issued a “buy” rating and a $172.00 price target on the stock. Finally, BMO Capital Markets lifted their price objective on BioNTech from $130.00 to $143.00 and gave the stock an “outperform” rating in a research note on Tuesday, March 11th. Three equities research analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $143.73.

BioNTech Price Performance

Shares of NASDAQ BNTX opened at $97.05 on Wednesday. The company has a fifty day moving average price of $112.45 and a 200 day moving average price of $113.84. BioNTech SE has a 1-year low of $76.53 and a 1-year high of $131.49. The firm has a market cap of $23.29 billion, a PE ratio of -46.21 and a beta of 0.30. The company has a current ratio of 7.33, a quick ratio of 7.21 and a debt-to-equity ratio of 0.01.

BioNTech (NASDAQ:BNTX) last announced its earnings results on Monday, March 10th. The company reported $1.08 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.38 by $0.70. The business had revenue of $1.19 billion for the quarter, compared to analyst estimates of $1.24 billion. BioNTech had a negative return on equity of 2.35% and a negative net margin of 15.16%. BioNTech’s revenue for the quarter was down 19.5% compared to the same quarter last year. During the same quarter last year, the firm earned $1.90 EPS. Research analysts predict that BioNTech SE will post -3.88 earnings per share for the current fiscal year.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.